![conference banner](/images/conference-banner.jpeg)
Abstract
One of the key players in many thrombotic complications is von Willebrand factor (VWF), a large, multimeric glycoprotein that is present in plasma where it fulfils a crucial role in haemostasis. First, VWF recruits platelets to vascular lesions by acting as a linker molecule between the exposed collagen and free-flowing platelets in the circulation. Second, by serving as a carrier protein for the coagulation factor VIII, VWF protects this anti-haemophilic factor from rapid degradation. Quantitative or qualitative defects in VWF result in the most common bleeding disorder in man, known as von Willebrand disease, illustrating the central role of VWF in haemostasis. On the other hand, a thrombotic risk emerges when over-reactive VWF molecules can bind spontaneously to platelets. It is clear that because of its pivotal role in maintaining the fine balance between bleeding and thrombosis, VWF is an attractive but delicate drug target. This review focuses on the role of VWF in both haemostasis and thrombosis with special attention to the molecule as drug and drug target respectively.
Cardiovascular & Hematological Disorders-Drug Targets
Title: Von Willebrand Factor: Drug and Drug Target
Volume: 9 Issue: 1
Author(s): Simon F. De Meyer, Bauke De Maeyer, Hans Deckmyn and Karen Vanhoorelbeke
Affiliation:
Abstract: One of the key players in many thrombotic complications is von Willebrand factor (VWF), a large, multimeric glycoprotein that is present in plasma where it fulfils a crucial role in haemostasis. First, VWF recruits platelets to vascular lesions by acting as a linker molecule between the exposed collagen and free-flowing platelets in the circulation. Second, by serving as a carrier protein for the coagulation factor VIII, VWF protects this anti-haemophilic factor from rapid degradation. Quantitative or qualitative defects in VWF result in the most common bleeding disorder in man, known as von Willebrand disease, illustrating the central role of VWF in haemostasis. On the other hand, a thrombotic risk emerges when over-reactive VWF molecules can bind spontaneously to platelets. It is clear that because of its pivotal role in maintaining the fine balance between bleeding and thrombosis, VWF is an attractive but delicate drug target. This review focuses on the role of VWF in both haemostasis and thrombosis with special attention to the molecule as drug and drug target respectively.
Export Options
About this article
Cite this article as:
De Meyer F. Simon, De Maeyer Bauke, Deckmyn Hans and Vanhoorelbeke Karen, Von Willebrand Factor: Drug and Drug Target, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/187152909787581327
DOI https://dx.doi.org/10.2174/187152909787581327 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Current Topics in Medicinal Chemistry Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology The Management of the Infected Diabetic Foot
Current Diabetes Reviews Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design MicroRNA in Aging: From Discovery to Biology
Current Genomics Biologic and Novel Therapy of the Inflammatory Bowel Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Development of New Fibrinolytic Agents
Current Pharmaceutical Design Antioxidant to Treat Osteoarthritis: Dream or Reality?
Current Drug Targets Adaptive and Compensatory Mechanisms of the Cardiovascular System and Disease Risk Factors in Young Males and Females
New Emirates Medical Journal Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Recent Advances in the Treatment Strategies of Friedreich’s Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms
Current Pharmaceutical Design Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism
Current Vascular Pharmacology Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cardiology Reviews